KR20160066185A - Composition for controlling sebum and reducing the skin pore containing icariside B2 - Google Patents

Abstract

The present invention relates to a composition for controlling sebum and reducing pore size and, more specifically, to a composition which can defend the skin against irritation, prevents large pores, provides an anti-oxidative effect, treats skin troubles, and control the generation of the sebum by comprising icariside B2.

Description

TECHNICAL FIELD The present invention relates to a composition for controlling sebum and reducing pores containing acaricide B2,

The present invention relates to a composition for regulating sebum and reducing pores, and more particularly, it relates to a composition for regulating sebum production by containing acaricide B2 and, at the same time, improving skin troubles, To prevent the pores from spreading, and to prevent the generation of skin irritation.

In general, sebaceous glands in the skin, including the scalp and face, play a role in preventing moisturization and microbial invasion of the skin. However, excessive secretion of sebum promotes hair loss, worsens acne, promotes enlargement of pores caused by acne, And many other diseases are caused.

The hypersecretion of sebaceous glands is caused by various causes, and the most important one is the activation of sebaceous glands by the amount of dihydrotestosterone (DHT), which is one of the hormones involved in promoting sebaceous secretion in the activity of sebaceous glands, Is overdone. That is, testosterone (T) is converted into dihydrotestosterone, one of the male hormones, by 5-alpha-reductase type 2 in cells in the hair loss, It binds to the receptor protein and enters the nucleus, causing hair loss. However, testosterone is converted to dihydrotestosterone by 5-α-reductase type 1 in skin or sebaceous glands, Activation to promote differentiation promotes sebum in the sebaceous glands and causes acne (J. Invest Dermatol 105: 209-214 Diane etc.).

Acne and hair loss, which are skin troubles other than simple sebum hypersecretion, are further exacerbated by the minute inflammatory reaction of the skin. If you look at the development of acne, excess sebum accumulates in the hair follicle, activating acne bacteria and causing inflammation.

However, there are not many raw materials that can reduce sebum secretion as a skin-safe natural material through fundamental causes.

On the other hand, Acaricide B2 can be isolated or chemically synthesized from terpenoid components extracted from a part of the perennial plant Asplenium scolopendrium belonging to the fern-tail gosarit (Natural Product Sciences, 14 (4): 265-268 (2008)). As to the icaricide compound icaride II (icariside II), whitening activity is already known (International Patent Publication No. WO 2008/035918, published on Mar. 27, 2008). On the other hand, a remarkable research result on icaricide B2, which is an icaricide compound, has not been reported yet.

Korean Patent Laid-Open No. 10-2012-0083943 (published on July 27, 2012) International Patent Publication No. WO 2008/035918 (published on Mar. 27, 2008)

Natural Product Sciences, 14 (4): 265-268 (2008)

Accordingly, the inventors of the present invention found that icaricide B2 is related to sebum control, antioxidant efficacy, prevention of pore enlargement prevention, and prevention of skin aging as a result of repeated studies on icaricide B2.

It is therefore an object of the present invention to provide compositions effective for sebum control and pore reduction.

In order to accomplish the above object, the present invention provides a composition for controlling sebum or reducing pores comprising acaricide B2, which is a compound represented by the following general formula (1), as an active ingredient.

The composition of the present invention not only has excellent sebum control or skin trouble improving effect by containing acaricide B2 but also reduces pore through removal of active oxygen and promoting collagen synthesis and has an effect of preventing generation of skin irritation due to excellent antioxidant power Excellent.

The composition according to the present invention can provide sebum control or pore reduction effect by containing acaricide B2 as an active ingredient.

Acaricide B2 used in the present invention is a compound having a structure represented by the following general formula (1), and has a molecular weight of 384 and megastigmene or 4- [2,2,6-trimethyl-4- (3,4,5 -Trihydro-pyran-2-yloxy) -7-oxa-bicyclo [4.1.0] hept-1-yl] 4- [2,2,6-Trimethyl-4- (3,4,5-trihydroxy-6-hydroxymethyl-tetrahydro-pyran-2-yloxy) -7-oxa-bicyclo [4.1.0] hept- ] -but-3-en-2-one).

[Chemical Formula 1]

The composition according to the present invention may contain acaricide B2 in an amount of 0.001 to 50% by weight, preferably 0.01 to 30% by weight, more preferably 0.1 to 10% by weight, based on the total weight of the composition. If the content of the acaricide B2 is less than 0.001% by weight, the effect and effect of the ingredient are insignificant, and if it exceeds 50% by weight, there is a problem of skin safety or shape.

The composition of the present invention may inhibit or inhibit the expression of the 5α-reductase gene or inhibit the activity of the 5α-reductase protein and may interfere with its action. When the composition is applied to the skin, The secreted sebum can be effectively inhibited.

In addition, the composition of the present invention exerts an effect of reducing active oxygen and promoting collagen synthesis to reduce pores, and suppressing skin troubles by decreasing the expression of inflammatory factors. In addition, excellent antioxidant power can prevent the generation of skin irritation.

The composition of the present invention may be formulated as an external preparation for skin, in particular as a cosmetic composition, and may be formulated containing a cosmetically or dermatologically acceptable medium or base. In addition, the composition of the present invention may be provided in any form suitable for topical application, for example, as a solution, an emulsion obtained by dispersing an oil phase in water phase, an emulsion obtained by dispersing water phase in water phase, a suspension, a solid, a gel, Pastes, foams, or aerosol compositions. Specifically, the composition of the present invention may be provided in the form of a cream, a skin, a lotion, a powder, an ointment, a spray or a cone stick. Compositions of such formulations may be prepared according to conventional methods in the art.

In particular, the composition for external application for skin of the present invention is not particularly limited as a composition for hair or scalp. For example, hair tonic, hair nutritional lotion, scalp treatment, hair treatment, hair shampoo, hair rinse, Scalp hair combined treatment, and the like.

In addition, the composition according to the present invention may contain, in addition to the above-mentioned substances, other ingredients which can give a synergistic effect to the main effect, to the extent that the main effect is not impaired. The composition according to the present invention may further comprise a humectant, an emollient, an ultraviolet absorber, an antiseptic, a bactericide, an antioxidant, a pH adjuster, an organic or inorganic pigment, a perfume, a cold agent or a limiting agent. The compounding amount of the above components can be easily selected by a person skilled in the art within the range not impairing the object and effect of the present invention, and the amount thereof may be from 0.01 to 5% by weight, specifically from 0.01 to 3% by weight based on the total weight of the composition .

In addition, the composition of the present invention can be formulated as a pharmaceutical composition. When the composition according to the present invention is applied to medicines, it may be formulated into oral, parenteral or parenteral dosage forms in solid, semi-solid or liquid form by adding an inorganic or organic carrier compatible with the active ingredient used in the present invention , The pharmaceutical composition according to the present invention may be administered orally, parenterally, rectally, topically, transdermally, intravenously, intramuscularly, intraperitoneally, subcutaneously, and the like.

Examples of the formulations for oral administration include tablets, pills, granules, capsules, powders, fine granules, powders, emulsions, syrups and pellets. In addition, the formulations for parenteral administration include injections, drops, ointments, lotions, sprays, suspensions, emulsions, suppositories, and the like. The composition according to the present invention can be easily formulated into an active ingredient by carrying out the composition according to a conventional method. In this case, a surfactant, excipient, coloring agent, spice, preservative, stabilizer, buffer, suspending agent, have.

The dosage of the active ingredient of the pharmaceutical composition of the present invention will vary depending on the age, sex, body weight, pathological condition and severity of the subject to be treated, route of administration, or judgment of the prescriber. Determination of the appropriate dose based on these factors is well within the level of ordinary skill in the art and its daily dose is, for example, from 0.1 mg / kg / day to 100 mg / kg / day, more specifically from 5 mg / kg / day to 50 mg / / Day, but is not limited thereto.

Hereinafter, the present invention will be described in more detail with reference to Examples. It is to be understood by those skilled in the art that these embodiments are only for illustrating the present invention and that the scope of the present invention is not construed as being limited by these embodiments.

[Reference Example 1] Preparation of acaricide B2

To test the efficacy of the compositions of the present invention, acaricide B2 was purchased from Simagchem Corporation (China).

[Test Example 1] 5 alpha -Reedtoise activity inhibitory effect

5α- Li deokte rise to ^[14 C] ratio of testosterone is converted to dihydrotestosterone ^[14 C] in HEK293-5αR2 cells was measured in order to determine the inhibitory effect. HEK293 cells were transfected with p3 x FLAG-CMV-5αR2 and cultured in 2.5 × 10 ⁵ cells per well on a 24-well plate (Park et al., 2003, JDS. Vol. 31, pp1 91-98) . The next day, the enzyme substrates and inhibitors were replaced with new media. 0.05 [mu] Ci [ ¹⁴ C] testosterone (Amersham Pharmacia biotech, UK) was used as the substrate of the medium. In order to confirm the degree of inhibition, 2 μg / ml of acaricide B2 was added as a test substance and cultured in a 5% CO ₂ incubator at 37 ° C. for 2 hours. At this time, for the purpose of comparison, those not containing the test substance were used as the negative control group, and 2μg / ml of the finasteride was used as the positive control group and cultured under the same conditions. The culture medium was collected and testosterone was extracted with 800 쨉 l of ethyl acetate. The upper organic solvent layer was separated and dried, and the remaining residue was dissolved again in 50 μl of ethyl acetate. Ethyl acetate-hexane (1: 1) was used as a developing solvent on a silica plastic sheet kiesel gel F254 Respectively.

After drying the plastic sample in air, the bath system was used to measure the amount of isotope. The dried plastic sheet and x-ray film were put together in a bath cassette. After 1 week, the testosterone and dihydrootestosterone isotope Small amounts were measured. The results are shown in Table 1 below.

sample Conversion Rate (%) Inhibition rate (%) Acaricide B2 28 35 Control group 48 - The positive control (Finasteride) 27 44

(1) Conversion rate: Radiation to DHT area / Total radioactivity

(2) Inhibition rate: 100 * (Conversion rate of control group - Conversion rate of sample) / Conversion rate of control group

From the results of the above Table 1, it can be seen that the acaricide B2 of the present invention converts testosterone into dihydrotestosterone, binds to a receptor protein in the cytoplasm, enters the nucleus, activates sebaceous gland cells and promotes differentiation, It was found that the inhibition of the activity of reductase effectively blocked the conversion of testosterone to dihydrotestosterone.

Therefore, the acaricide B2 of the present invention is effective for inhibiting the hypersecretion of sebum because it has an excellent 5α-reductase activity inhibitory effect.

[Reference Example 2] Preparation of Example 1 and Comparative Example 1

Example 1 and Comparative Example 1 of lotion formulations were prepared in a conventional manner (unit: wt%) according to the composition shown in Table 2 below.

number Raw material name Example 1 Comparative Example 1 One Cetearyl alcohol 1.0 1.0 2 Chin type glyceryl stearate 1.0 1.0 3 Glyceryl stearate SE 1.5 1.5 4 Phitosqualan 3 3 5 Hydrogenated Polydecenes 2 2 6 Dimethicone 0.5 0.5 7 Polysorbate 60 One One 8 Sorbitan sesquioleate 0.4 0.4 9 Methylparaben 0.1 0.1 10 Propylparaben 0.05 0.05 11 Purified water To 100 To 100 12 Butylene glycol 5 5 13 Polyacrylate-13 * polyisobutene * polysorbate 20 0.5 0.5 14 Acaricide B2 One -

<Manufacturing Method of Example 1 and Comparative Example 1>

1) Components 11 to 14 were uniformly mixed while heating to 70 캜 to prepare a water-based part.

2) The above components 1 to 10 were uniformly mixed while heating to 70 ° C to prepare an oil phase part.

3) The oil phase part of 2) was put into the water phase part of the above 1) and homomixed at 7,200 rpm for 6 minutes.

4) The mixture of 3) was cooled to room temperature.

[Test Example 2] Effect of suppressing sebum secretion

To evaluate sebum secretion inhibiting effects of Example 1 and Comparative Example 1, the following evaluation was made. Twenty male and female subjects who felt that sebum secretion was high were selected and divided into two groups of ten, and the lotions of Example 1 and Comparative Example 1 were each divided into two groups for each week for four weeks. The determination of the effect of sebum reduction was made using a sebum level meter (Sebumeter 815, Germany) and the results are shown in Table 3 below.

Example 1 Comparative Example 1 Average fat reduction rate after 2 weeks (%) 29 5 Average fat reduction rate (%) after 4 weeks 31 5

From the results shown in Table 3, it can be seen that Example 1 containing acaricide B2 according to the present invention can effectively inhibit excess sebum secreted from Comparative Example 1 which does not contain these substances.

Accordingly, the composition for external application for skin according to the present invention has an excellent sebum secretion inhibiting effect.

[Test Example 3] Reduction of skin inflammatory factor expression

The anti - inflammatory effect was evaluated by the inhibitory effect of prostaglandin production. The effect of acaricide B2 on macrophages was measured. First, aspirin was added to the mouse macrophages (cell line: RAW 264.7; available from ATCC) to a final concentration of 500M to irreversibly remove the remaining cyclooxygenase (COX) activity in the cells Respectively. Then, the suspension was added to each well of a 96-well cell culture tube in an amount of 100 μl, followed by culturing in an incubator of 5% CO ₂ and 37 ° C for 2 hours to adhere macrophages to the surface of the container. Then, the adhered macrophages were washed three times with PBS and used for the inflammation improving effect test. RPMI medium containing 1% (w / v) LPS was added to the cultured macrophage 5x10 ⁴ cells / ml and cultured for 12 hours to induce the production of prostaglandin. 100 μl of acaricide B2 was treated with the free prostaglandin Were quantitated using enzyme immunoassay (ELISA).

At this time, the inhibitory activity on the production of prostaglandin of acaricide B2 was determined by setting the difference of the prostaglandins produced in the LPS-treated group and the untreated group to 100%, and treating the LPS and the sample together to obtain a reduced percentage of prostaglandin (Control effect of prostaglandin production) is shown in Table 4 below.

Blank 100% Control group (aspirin treatment group) 25.0% Acaricide B2 39.0%

As shown in Table 4, it was found that the effect of inhibiting the production of prostaglandin was high even when the acaricide B2 was treated.

As a result, it can be seen that the acaricide B2 of the present invention inhibits the expression of prostaglandin, which is a skin inflammation factor, to provide excellent inflammation improving effect and also can prevent and improve skin troubles.

2. IL-8 production inhibitory effect

The day before the experiment, the skin keratinocyte (NHEK, available from Lonza) was dispensed into a 96 well plate at 5 × 10 ⁴ cells / well, and incubated at 37 ° C. in a 5% CO ₂ incubator. For 24 hours. Twenty-four hours later, the cells were washed twice with PBS and replaced with serum free keratinocyte basement media (KBM). Acaricide B2 was treated with each concentration of the following Table 5 for 30 minutes, and treated with PGSA (50 μg / ml) + LPS (1 μg / ml), respectively. For comparison, PGSA (10 μg / ml), PGSA (50 μg / ml), PGSA (50 μg / ml) and LPS (1 μg / ml) were treated in wells not treated with acaricide B2. Here, peptidoglycan from S. aureus (PGSA ) is a peptidoglycan extracted from Staphylococcus aureus , which is a major constituent of the cell wall of Gram-positive (+) bacteria, and the cell membrane components of bacteria are known to cause inflammation, Especially in staphylococcus, about 90% of atopic patients are reported to cause secondary infection by this bacterium. LPS (lypopolysaccaride) is a major constituent of Gram negative (-) bacterial cell membrane and is known to be the main cause of inflammation.

After culturing in a 5% CO ₂ incubator at 37 ° C for 24 hours, the culture was taken and ELISA for interleukin-8 (IL-8) was performed. The results are shown in Table 5 below. The ELISA used the experimental method of BD science.

division IL-8 secretion (pg / ml) Untreated Control (Control) 935.12 PGSA (10 [mu] g / ml) 4812.60 PGSA (50 占 퐂 / ml) 5895.08 PGSA (50 占 퐂 / ml) + LPS (1 占 퐂 / ml) 6814.91 Acaricide B2 (5 ppm) 3728.15 Acaricide B2 (25 ppm) 3664.41 Acaricide B2 (50 ppm) 3578.11

In Table 5, it was confirmed that the saccharide B2 significantly decreased and suppressed the secretion of IL-8 increased by PGSA and LPS. Therefore, it can be seen that the composition for external application for skin of the present invention can provide a superior anti-inflammatory effect by significantly reducing the secretion of IL-8 increased by PGSA and LPS.

[Test Example 4] Inhibitory effect on the production of reactive oxygen species

Keratinocyte (cell line: HaCaT; available from ATCC) was cultured in a 24 well cell culture medium containing keratinocyte growth media (Clonetics, BioWhittacker, MD, USA) 5 x 10 ⁴ pieces were put into each well of the plate and adhered for 24 hours. After the culture solution was removed, 100 μl of phosphate buffered saline (PBS) was added to each well. The keratinocytes were irradiated with ultraviolet rays of 30 mJ / cm 2 using an ultraviolet B (UVB) lamp (Model: K5T8, UVB 15W, Sankyo Dennki, Japan), and PBS was removed. Was added. The amount of reactive oxygen species (ROS) increased by ultraviolet stimulation was determined at a time interval of 2 μg / ml of acaricide B2 as a test substance. At this time, for comparison, the amounts of active oxygen species were measured without treatment of the test substance (untreated), with no ultraviolet stimulation, and with ultraviolet stimulation without treatment of the test substance. The amount of ROS was determined by referring to Tan's method of measuring the fluorescence of DCF-DA (dichlorofluorescin diacetate) oxidized by ROS (Tan et al., 1998, J. Cell Biol. Vol. 141, pp1423-1432) The ratios of the control group to ROS are shown in Table 6 below.

UVB 30 mJ / cm ² Elapsed time after irradiation 0 hours 2 hours 3 hours No treatment 100 244 287 UVB + no treatment 100 325 381 UVB + acaricide B2 100 278 324

From the results shown in the above Table 6, it can be seen that the acaricide B2 of the present invention effectively inhibits the production of ROS, which is known to cause skin cell damage by ultraviolet rays, and thus these substances are found to be excellent in antioxidant efficacy have.

Therefore, it can be seen that the alkaliside B2 contained in the composition of the present invention can prevent the widening of pores by inhibiting oxidation and preventing aging, and can prevent the generation of skin irritation.

[Test Example 5] Promotion of collagen biosynthesis

The collagen biosynthesis promotion effect of the acaricide B2 used in the present invention was measured in comparison with TGF-beta.

First, 10 ⁵ fibroblasts (cell line: KF-4109; available from Klebosha) were seeded into each well of a 24-well plate and cultured until they grew to about 90%. After culturing for 24 hours in serum-free DMEM medium, acaricide B2 and TGF-beta were each treated with 2 μg / ml and cultured in a CO ₂ incubator for 24 hours. The supernatant was removed and the procolagen (I) ELISA kit (procollagen type (I)) was used to determine whether procollagen was increased or decreased. The results are shown in Table 7, and the combined performance of the collagen was compared with that of the untreated group.

division Collagen Total Performance (%) Untreated group 100 TGF-beta 183.5 Acaricide B2 174.6

From the results shown in Table 7, it was confirmed that the acaricide B2 of the present invention exhibited high collagen aggregation performance.

Thus, it can be seen that the acaricide B2 of the present invention can increase the amount of collagen produced around the pore, thereby widening the pores.

[Reference Example 3] Preparation of Example 2 and Comparative Example 2

According to the composition shown in Table 8 below, Example 2 and Comparative Example 2 of the softening longevity (skin lotion) formulation were prepared by a conventional manufacturing method (unit: wt%).

Compounding ingredient Example 2 Comparative Example 2 Purified water Balance Balance Acaricide B2 0.1 - Butylene glycol 2.0 2.0 Propylene glycol 2.0 2.0 Carboxyvinyl polymer 0.1 0.1 Phage-12 nonylphenyl ether 0.2 0.2 Polysorbate 80 0.4 0.4 ethanol 10.0 10.0 Triethanolamine 0.1 0.1 Preservative, coloring, fragrance Suitable amount Suitable amount

[Test Example 6] Sensory evaluation on pore contraction

The test subjects were randomly divided into two groups of 15 individuals, each of which had a 30- to 50-year-old female oily skin owner. Each group was coated with the products of Example 2 or Comparative Example 2 after a certain period of time after cleansing, and was performed twice a day in the morning and evening, and after 4 weeks, the pore size was visually measured . The results are shown in Table 9 below (evaluation grade: 0. not reduced at all; 5. highly reduced)

division Rating Rating Example 2 3.3 Comparative Example 2 0.8

As can be seen from the results shown in Table 9, the composition containing the alkaline seed B2 of the present invention (Example 2) was significantly superior to the composition containing no pore-shrinking effect (Comparative Example 2) There were many.

Thus, it was found that the pore-shrinking effect of the external preparation for skin containing the acaricide B2 of the present invention was excellent.

Hereinafter, formulation examples of the composition according to the present invention will be described. However, the pharmaceutical composition and the cosmetic composition can be applied to various formulations, and the present invention is not limited thereto but is specifically described.

[Formulation Example 1] Lotion

Lotions are prepared according to a conventional method with the composition shown in Table 10 below.

Content (% by weight) Acaricide B2 2.0 glycerin 3.0 Butylene glycol 2.0 Propylene glycol 2.0 Carboxyvinyl polymer 0.1 PEG 12 nonyl phenyl ether 0.2 Polysorbate 80 0.4 ethanol 10.0 Triethanolamine 0.1 Preservative, coloring, fragrance Suitable amount Purified water Balance

[Formulation Example 2] Nourishing cream

Nutritive creams are prepared according to the usual methods with the compositions shown in Table 11 below.

Content (% by weight) Acaricide B2 2.0 Polysorbate 60 1.5 Sorbitan sesquioleate 0.5 PEG 60 hardened castor oil 2.0 Liquid paraffin 10.0 Squalane 5.0 Caprylic / caproic triglyceride 5.0 glycerin 5.0 Butylene glycol 3.0 Propylene glycol 3.0 Triethanolamine 0.2 Preservative, coloring, fragrance Suitable amount Purified water Balance

[Formulation Example 3] Massage cream

A massage cream is prepared according to a conventional method with the composition shown in Table 12 below.

Content (% by weight) Acaricide B2 1.0 Wax 10.0 Polysorbate 60 1.5 PEG 60 hardened castor oil 2.0 Sorbitan sesquioleate 0.8 Liquid paraffin 40.0 Squalane 5.0 Caprylic / capric triglyceride 4.0 glycerin 5.0 Butylene glycol 3.0 Propylene glycol 3.0 Triethanolamine 0.2 Preservative, coloring, fragrance Suitable amount Purified water Balance

[Formulation Example 4] Pack

A pack is prepared according to a conventional method with the composition shown in Table 13 below.

Content (% by weight) Acaricide B2 1.0 Polyvinyl alcohol 13.0 Sodium carboxymethylcellulose 0.2 glycerin 5.0 Allantoin 0.1 ethanol 6.0 PEG 12 nonyl phenyl ether 0.3 Polysorbate 60 0.3 Preservative, coloring, fragrance Suitable amount Purified water Balance

[Formulation Example 5] Gel

A gel is prepared according to a conventional method with the composition shown in Table 14 below.

Content (% by weight) Acaricide B2 0.5 Ethylenediamine sodium acetate 0.05 glycerin 5.0 Carboxyvinyl polymer 0.3 ethanol 5.0 PEG 60 hardened castor oil 0.5 Triethanolamine 0.3 Preservative, coloring, fragrance Suitable amount Purified water Balance

[Formulation Example 6] Ointment

Ointment was prepared in a conventional manner with the composition shown in Table 15 below.

Content (% by weight) Acaricide B2 0.1 glycerin 8.0 Butylene glycol 4.0 Liquid paraffin 15.0 Beta Glucan 7.0 Carbomer 0.1 Caprylic / capric triglyceride 3.0 Squalane 1.0 Cetearyl glucoside 1.5 Sorbitan stearate 0.4 Cetearyl alcohol 1.0 Wax 4.0 Preservative, coloring, fragrance Suitable amount Purified water Balance

[Formulation Example 7] Soft capsule

A soft capsule was prepared by mixing 0.0025 g of acaricide B2, 0.0025 g of vitamin C, 2 mg of palm oil, 8 mg of palm kernel oil, 4 mg of yellow radish and 6 mg of lecithin and filling with 400 mg per capsule according to a conventional method.

[Formulation Example 8] Tablets

0.0025 g of acaricide B2, 0.0025 g of vitamin C, 100 mg of glucose, 96 mg of starch and 4 mg of magnesium stearate were mixed and 40 mg of 30% ethanol was added to form granules. The granules were dried at 60 ° C and tableted by tableting using a tablet machine .

[Formulation Example 9]

The mixture was mixed with 150 mg of acaricide B2, 150 mg of vitamin C, 100 mg of glucose, and 600 mg of starch, and 100 mg of 30% ethanol was added to form granules, followed by drying at 60 ° C to form granules. The final weight of the contents was 1 g.

[Formulation Example 10]

0.0025 g of acaricide B2, 0.0025 g of vitamin C, 10 g of glucose, 2 g of citric acid and 187.8 g of purified water were mixed and filled in a bottle. The final volume of the contents was adjusted to 200 ml.

While the present invention has been particularly shown and described with reference to specific embodiments thereof, those skilled in the art will readily appreciate that many modifications are possible in the exemplary embodiments without materially departing from the novel teachings and advantages of this invention. something to do. Accordingly, the actual scope of the present invention will be defined by the appended claims and their equivalents.

Claims (6)

A composition for controlling sebum comprising an acaricide B2 represented by the following formula (1) as an active ingredient.
[Chemical Formula 1]

1. A composition for improving skin trouble comprising acaricide B2 represented by the following formula (1) as an active ingredient.
[Chemical Formula 1]

A composition for shrinking a pore containing an alkaline seed (B2) represented by the following formula (1) as an active ingredient.
[Chemical Formula 1]

A composition for preventing the enlargement of pores, which comprises an acaricide B2 represented by the following general formula (1) as an active ingredient.
[Chemical Formula 1]

The composition according to any one of claims 1 to 4, wherein the active ingredient is contained in an amount of 0.001 to 50% by weight based on the total weight of the composition. 5. The composition according to any one of claims 1 to 4, wherein the composition is a cosmetic composition.